



University of Dundee

Guidelines for the management of diabetes services and patients during the COVID-19 pandemic

Rayman, G.; Lumb, A.; Kennon, B.; Cottrell, C.; Nagi, D.; Page, E.

Published in:
Diabetic Medicine

DOI:
[10.1111/dme.14316](https://doi.org/10.1111/dme.14316)

Publication date:
2020

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Rayman, G., Lumb, A., Kennon, B., Cottrell, C., Nagi, D., Page, E., Voigt, D., Courtney, H., Atkins, H., Platts, J., Higgins, K., Dhatariya, K., Patel, M., Narendran, P., Kar, P., Newland-Jones, P., Stewart, R., Burr, O., Thomas, S. (2020). Guidelines for the management of diabetes services and patients during the COVID-19 pandemic. *Diabetic Medicine*, 37(7), 1087-1089. <https://doi.org/10.1111/dme.14316>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

DR GERRY RAYMAN (Orcid ID : 0000-0003-3331-7015)

DR ALISTAIR NATHAN LUMB (Orcid ID : 0000-0001-7041-9534)

MRS EMMA PAGE (Orcid ID : 0000-0002-6998-7064)

PROFESSOR KETAN DHATARIYA (Orcid ID : 0000-0003-3619-9579)

DR MAYANK PATEL (Orcid ID : 0000-0002-6609-5394)

Article type : Diabetes UK Position Statements

Title: Diabetic Medicine

Created by: Maria Hale

Email proofs to: ketan.dhatariya@nnuh.nhs.uk Copyright: Diabetes UK

Article no.: DME-2020-00270

Article type: Position Statement

Short title/Authors running head: *Diabetes UK Position Statements • G. Rayman et al.*

Guidelines for the management of diabetes services and patients during the COVID-19 pandemic

G. Rayman¹, A. Lumb³, B. Kennon⁴, C. Cottrell⁵, D. Nagi⁶, E. Page², D. Voigt⁷,
H. Courtney⁸, H. Atkins⁹, J. Platts¹⁰, K. Higgins⁹, K. Dhatariya¹¹, M. Patel¹², P.
Narendran¹³, P. Kar¹⁴, P. Newland-Jones¹², R. Stewart¹⁵, O. Burr¹⁶ and S.
Thomas¹⁷, on behalf of the London Inpatient Diabetes Network-COVID-19

¹Ipswich Hospital and ²Ipswich Diabetes Centre, East Suffolk and North East Essex NHS Foundation Trust, Ipswich, ³Oxford University Hospitals NHS Foundation Trust, Oxford, ⁴Queen Elizabeth University Hospital, Glasgow, ⁵Swansea Bay University Health Board, Port Talbot, ⁶Mid Yorkshire NHS Trust, Wakefield,

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dme.14316. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

This article is protected by copyright. All rights reserved

⁷Ninewells Hospital, Dundee, ⁸Belfast Health & Social Care Trust, Belfast, ⁹University Hospitals of Leicester, Leicester, ¹⁰Cardiff and Vale University Health Board, Cardiff, ¹¹Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, ¹²University Hospital Southampton NHS Foundation Trust, Southampton, ¹³Queen Elizabeth Hospital, Birmingham, Birmingham, ¹⁴Portsmouth Hospitals NHS Trust, Portsmouth, ¹⁵Wrexham Maelor Hospital, Betsi Cadwaladr University Health Board, Wrexham, and ¹⁶DiabetesUK and ¹⁷Guy's and St Thomas' NHS Foundation Trusts, London, UK

Correspondence to: Gerry Rayman. E-mail: gerry.rayman@esneft.nhs.uk

Abstract

The UK National Diabetes Inpatient COVID Response Group was formed at the end of March 2020 to support the provision of diabetes inpatient care during the COVID pandemic. It was formed in response to two emerging needs. First to ensure that basic diabetes services are secured and maintained at a time when there was a call for re-deployment to support the need for general medical expertise across secondary care services. The second was to provide simple safe diabetes guidelines for use by specialists and non-specialists treating inpatients with or suspected of COVID-19 infection. To date the group, comprising UK-based specialists in diabetes, pharmacy and psychology, have produced two sets of guidelines which will be continually revised as new evidence emerges. It is supported by Diabetes UK, the Association of British Clinical Diabetologists and NHS England.

What's new?

- Diabetes specialist services help avoid unnecessary admission and readmission of people with diabetes to secondary care facilities and inpatient teams facilitate their care whilst admitted.
- Clinicians and trainees without diabetes expertise are providing diabetes care during the COVID-19 pandemic.
- This Position Statement outlines the need to maintain key elements of specialist diabetes services with a focus on delivering safe inpatient diabetes care.
- The Position Statement also outlines simple pathways for the management of inpatients with diabetes by admitting teams in secondary care.
- This Position Statement will be useful to trusts/health boards in redesigning clinical services during the COVID-19 pandemic and helping ensure that the safe care of people with diabetes.

The COVID-19 pandemic presents the greatest challenge to healthcare delivery in living memory, and the impact on community and specialist diabetes services has been immense [1]. Many existing services have been suspended and in some areas, all diabetes staff (including inpatient specialist nurses) redeployed to support general inpatient care. This has been done at short notice and without full consideration of the important role diabetes teams play in preventing harm to people with diabetes, both in hospital and in the community.

Several weeks into the pandemic, it has become increasingly apparent that support from inpatient diabetes specialists is essential. The management of people with diabetes who are acutely unwell with suspected or confirmed COVID-19 is complex [2], and many of the staff recruited to the front line are unfamiliar with managing people with diabetes. Furthermore,

systems need to be in place in the community to facilitate and support early discharge and prevent readmission of people with diabetes, particularly those who have been newly started on insulin in whom rapid dose reduction is often required.

In the response to these challenges, the National Diabetes Inpatient COVID-19 Resource Group was formed in the last week of March 2020. The group comprises specialists in diabetes, pharmacy and psychology. To date the group have produced two sets of documents available on the Association of British Clinical Diabetologists and Diabetes UK web sites.

The first set

(https://abcd.care/sites/abcd.care/files/site_uploads/To%20the%20Diabetes%20Team_Final%20%28004%29.docx), aimed at specialist teams and managers, outlines key service requirements vital to maintain patient safety while accelerating flow through the hospital.

This is in addition to maintaining delivery of closely managed outpatient and community services to prevent avoidable admissions and readmissions

(<https://abcd.care/resource/maintaining-acute-diabetes-services-response-covid-19>). To help plan services, an easy to use template based on the NHS 'Clinical guide for the management of acute diabetes patients during the coronavirus pandemic' [5], is provided as well as a completed template as an example of how one service has redeployed their staff

(<https://abcd.care/resource/template-defining-diabetes-services-during-covid-19-pandemic> or <https://www.diabetes.org.uk/professionals/resources/coronavirus-clinical-guidance>).

The second three-page document, aimed at emergency departments and acute admitting teams provides guidance and an algorithm for diabetes management at the 'front door' (Fig. 1) (<https://abcd.care/resource/concise-advice-inpatient-diabetes-during-covid19-front-door-guidance> and <https://www.diabetes.org.uk/professionals/resources/coronavirus-clinical-guidance>). It recognizes that a significant number of COVID-19 positive patients not

previously known to have diabetes may present with significant hyperglycaemia and therefore recommends blood glucose should be measured in all admissions. Additionally, anecdotal reports suggest unusual presentations of diabetic metabolic emergencies including people with type 2 diabetes presenting in diabetic ketoacidosis or mixed ketoacidosis and hyperosmolar hyperglycaemic state. It thus recommends that ketones be checked in everyone with known diabetes, and those without known diabetes who present with a blood glucose > 12 mmol/l whether or not they are treated with sodium–glucose co-transporter 2 inhibitors. The document contains a table outlining key differences seen in COVID positive patients based on experience from UK centres with the greatest experience of looking after these patients. There is also brief advice on glycaemic management, blood ketone levels, insulin management, patients using subcutaneous pumps and finally foot care.

The National Inpatient Diabetes COVID19 Response Group will continue to update these documents as more evidence becomes available, and will shortly be releasing guidance on the use of subcutaneous insulin for managing hyperglycaemia as well as for managing ketoacidosis in the event of intravenous insulin infusion pumps being unavailable because of increased demands for use to deliver other therapies. The group is also continuing to work on patient-facing resources to support preparation for any potential hospital admission, and safe discharge advice for inpatient staff.

Funding sources

None.

Competing interests

None declared.

Acknowledgements

We would like to thank London Inpatient Diabetes Network-COVID-19 for sharing their experiences in managing people with diabetes and COVID-19.

References

- 1 Ma RCW, Holt RIG. COVID-19 and diabetes. *Diabet Med* 2020; **37**: 723–725.
- 2 Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M *et al.* Comorbid diabetes mellitus was associated with poorer prognosis in patients with COVID-19: a retrospective cohort study. medRxiv. Available at <https://www.medrxiv.org/content/10.1101/2020.03.24.20042358v1> Last accessed X XX 2020.
- 3 Royal College of Physicians; Association of British Clinical Diabetologists; NHS. *Clinical Guide for the Management of People with Diabetes During the Coronavirus Pandemic*, March 2020. Available at <https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/speciality-guide-diabetes-19-march-v2-updated.pdf> Last accessed X XX 2020.

FIGURE 1 Concise advice on inpatient diabetes.

COncise adVice on Inpatient Diabetes (COVID:Diabetes): FRONT DOOR GUIDANCE

DIABETES UK
KNOW DIABETES. FIGHT DIABETES.



NATIONAL INPATIENT DIABETES COVID-19 RESPONSE GROUP

▲ COVID-19 infection in people with or without previously recognised diabetes increases the risk of the EMERGENCY states of hyperglycaemia with ketones, Diabetic KetoAcidosis (DKA) and Hyperosmolar Hyperglycaemic State (HHS)

Being acutely unwell with suspected/confirmed COVID-19 requires adjustment to standard approaches to diabetes management (see table below).

The guidance in this document is based on experience from UK centres with the greatest experience of looking after patients with COVID-19 disease and will be updated as more evidence becomes available.

WHERE CHANGE SEEN	KEY DIFFERENCE WITH COVID-19	SUGGESTED ACTION
Early in admission	<p>People with COVID-19 infection appear to have a greater risk of hyperglycaemia with ketones including:</p> <ul style="list-style-type: none"> > People with type 2 diabetes (risk even greater if on a SGLT-2 inhibitor) > People with newly diagnosed diabetes <p>COVID-19 disease precipitates atypical presentations of diabetes emergencies (eg. mixed DKA and hyperosmolar states)</p>	<ul style="list-style-type: none"> > Check blood glucose in everybody on admission > Check ketones in: <ul style="list-style-type: none"> » everybody with diabetes being admitted » everybody with an admission glucose over 12 mmol/l > Stop SGLT-2 inhibitors in all people admitted to hospital > Stop Metformin in all people admitted to hospital but review when data on blood lactate, renal and hypoxic status are available. > Consider using 10-20% glucose where ketosis persists despite treatment in line with usual protocols
Severe illness on admission	<p>Fluid requirements may differ in those with DKA/HHS and evidence of "lung leak" or myocarditis</p>	<ul style="list-style-type: none"> > After restoring the circulating volume the rate of fluid replacement regimen may need to be adjusted where evidence of "lung leak" or myocarditis > Contact the diabetes specialist team early > Early involvement of the critical care team
All inpatient areas	<p>Infusion pumps may not be available to manage hyperglycaemia using intravenous insulin as these are required elsewhere (eg for sedation in ICU)</p>	<ul style="list-style-type: none"> > Use alternative s/c regimens to manage <ul style="list-style-type: none"> » Hyperglycaemia » Mild DKA > Contact the diabetes specialist team for support
ICU	<p>Significant insulin resistance seen in people with type 2 diabetes in ICU settings</p>	<ul style="list-style-type: none"> > IV insulin protocols may need amending (people seen requiring up to 20 units/hr) > Patients often nursed prone so feeding may be accidentally interrupted – paradoxical risk of hypoglycaemia